• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ESC Heart Fail . The prognostic value of serial troponin measurements in patients admitted for COVID-19

tetano

Editor, Senior Moderator
ESC Heart Fail


. 2021 Jul 8.
doi: 10.1002/ehf2.13462. Online ahead of print.
The prognostic value of serial troponin measurements in patients admitted for COVID-19


Vincenzo Nuzzi[SUP] 1 [/SUP], Marco Merlo[SUP] 1 [/SUP], Claudia Specchia[SUP] 2 [/SUP], Carlo Mario Lombardi[SUP] 3 [/SUP], Valentina Carubelli[SUP] 3 [/SUP], Annamaria Iorio[SUP] 4 [/SUP], Riccardo Maria Inciardi[SUP] 3 [/SUP], Antonio Bellasi[SUP] 5 [/SUP], Claudia Canale[SUP] 6 [/SUP], Rita Camporotondo[SUP] 7 [/SUP], Francesco Catagnano[SUP] 8 [/SUP], Laura Adelaide Dalla Vecchia[SUP] 9 [/SUP], Stefano Giovinazzo[SUP] 6 [/SUP], Gloria Maccagni[SUP] 3 10 [/SUP], Massimo Mapelli[SUP] 11 12 [/SUP], Davide Margonato[SUP] 8 [/SUP], Luca Monzo[SUP] 13 14 [/SUP], Chiara Oriecuia[SUP] 2 3 [/SUP], Giulia Peveri[SUP] 2 12 [/SUP], Andrea Pozzi[SUP] 4 [/SUP], Giovanni Provenzale[SUP] 15 [/SUP], Filippo Sarullo[SUP] 16 [/SUP], Daniela Tomasoni[SUP] 3 [/SUP], Pietro Ameri[SUP] 6 [/SUP], Massimiliano Gnecchi[SUP] 7 17 [/SUP], Sergio Leonardi[SUP] 7 17 [/SUP], Piergiuseppe Agostoni[SUP] 11 12 [/SUP], Stefano Carugo[SUP] 15 [/SUP], Gian Battista Danzi[SUP] 10 [/SUP], Marco Guazzi[SUP] 18 19 [/SUP], Maria Teresa La Rovere[SUP] 20 [/SUP], Andrea Mortara[SUP] 8 [/SUP], Massimo Piepoli[SUP] 21 22 [/SUP], Italo Porto[SUP] 6 [/SUP], Maurizio Volterrani[SUP] 23 [/SUP], Michele Senni[SUP] 4 [/SUP], Marco Metra[SUP] 3 [/SUP], Gianfranco Sinagra[SUP] 1 [/SUP]



Affiliations
Free article

Abstract

Aims: Myocardial injury (MI) in coronavirus disease-19 (COVID-19) is quite prevalent at admission and affects prognosis. Little is known about troponin trajectories and their prognostic role. We aimed to describe the early in-hospital evolution of MI and its prognostic impact.
Methods and results: We performed an analysis from an Italian multicentre study enrolling COVID-19 patients, hospitalized from 1 March to 9 April 2020. MI was defined as increased troponin level. The first troponin was tested within 24 h from admission, the second one between 24 and 48 h. Elevated troponin was defined as values above the 99th percentile of normal values. Patients were divided in four groups: normal, normal then elevated, elevated then normal, and elevated. The outcome was in-hospital death. The study population included 197 patients; 41% had normal troponin at both evaluations, 44% had elevated troponin at both assessments, 8% had normal then elevated troponin, and 7% had elevated then normal troponin. During hospitalization, 49 (25%) patients died. Patients with incident MI, with persistent MI, and with MI only at admission had a higher risk of death compared with those with normal troponin at both evaluations (P < 0.001). At multivariable analysis, patients with normal troponin at admission and MI injury on Day 2 had the highest mortality risk (hazard ratio 3.78, 95% confidence interval 1.10-13.09, P = 0.035).
Conclusions: In patients admitted for COVID-19, re-test MI on Day 2 provides a prognostic value. A non-negligible proportion of patients with incident MI on Day 2 is identified at high risk of death only by the second measurement.

Keywords: COVID-19; COVID-19 outcome; Myocardial injury; Troponin trajectories.
 
Back
Top Bottom